Skip to main content
. 2015 Aug;4(4):465–474. doi: 10.3978/j.issn.2218-6751.2015.07.17

Figure 3.

Figure 3

Progression-free survival (PFS) analysis of patients with documented wildtype EGFR in the BR.21 and SATURN intention-to-treat populations. (A) PFS for the combined BR.21 and SATURN wildtype sub-populations; (B) forest plot of PFS hazard ratios (HR) for the individual and combined (BR.21 and SATURN) wildtype sub-populations; (C) forest plot of PFS for the combined (BR.21 and SATURN) wildtype sub-populations where we estimate the HR’s within baseline sub-populations. EGFR, epidermal growth factor receptor; Erl, erlotinib; PBO, placebo; ECOG, Eastern Cooperative Oncology Group; PS, performance status.